Subtype and regional-specific neuroinflammation in sporadic creutzfeldt-jakob disease

dc.contributor.author
Llorens Torres, Franc
dc.contributor.author
López González, Irene
dc.contributor.author
Thüne, Katrin
dc.contributor.author
Carmona Murillo, Margarita
dc.contributor.author
Zafar, Saima
dc.contributor.author
Andréoletti, Olivier
dc.contributor.author
Zerr, Inga
dc.contributor.author
Ferrer, Isidro (Ferrer Abizanda)
dc.date.issued
2015-10-29T15:27:13Z
dc.date.issued
2015-10-29T15:27:13Z
dc.date.issued
2014-08-04
dc.date.issued
2015-10-29T15:27:13Z
dc.identifier
1663-4365
dc.identifier
https://hdl.handle.net/2445/67536
dc.identifier
647684
dc.identifier
25136317
dc.description.abstract
The present study identifies deregulated cytokines and mediators of the immune response in the frontal cortex and cerebellum of sporadic Creutzfeldt-Jakob disease (sCJD) MM1 and VV2 subtypes compared to age-matched controls. Deregulated genes include pro- and anti-inflammatory cytokines, toll-like receptors, colony stimulating factors, cathepsins, members of the complement system, and members of the integrin and CTL/CTLD family with particular regional and sCJD subtype patterns. Analysis of cytokines and mediators at protein level shows expression of selected molecules and receptors in neurons, in astrocytes, and/or in microglia, thus suggesting interactions between neurons and glial cells, mainly microglia, in the neuroinflammatory response in sCJD. Similar inflammatory responses have been shown in the tg340 sCJD MM1 mice, revealing a progressive deregulation of inflammatory mediators with disease progression. Yet, inflammatory molecules involved are subjected to species differences in humans and mice. Moreover, inflammatory-related cell signaling pathways NFκB/IKK and JAK/STAT are activated in sCJD and sCJD MM1 mice. Together, the present observations show a self-sustained complex inflammatory and inflammatory-related responses occurring already at early clinical stages in animal model and dramatically progressing at advanced stages of sCJD. Considering this scenario, measures tailored to modulate (activate or inhibit) specific molecules could be therapeutic options in CJD.
dc.format
16 p.
dc.format
application/pdf
dc.language
eng
dc.publisher
Frontiers Media
dc.relation
Reproducció del document publicat a: http://dx.doi.org/10.3389/fnagi.2014.00198
dc.relation
Frontiers in Aging Neuroscience, 2014, vol. 6, p. 198
dc.relation
http://dx.doi.org/10.3389/fnagi.2014.00198
dc.relation
info:eu-repo/grantAgreement/EC/FP7/278486/EU//DEVELAGE
dc.relation
info:eu-repo/grantAgreement/EC/FP7/222887/EU//PRIORITY
dc.rights
cc-by (c) Llorens, Franc et al., 2014
dc.rights
http://creativecommons.org/licenses/by/3.0/es
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Patologia i Terapèutica Experimental)
dc.subject
Malaltia de Creutzfeldt-Jakob
dc.subject
Inflamació
dc.subject
Malalties per prions
dc.subject
Citoquines
dc.subject
Creutzfeldt-Jakob disease
dc.subject
Inflammation
dc.subject
Prion diseases
dc.subject
Cytokines
dc.title
Subtype and regional-specific neuroinflammation in sporadic creutzfeldt-jakob disease
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.